Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection

Int J Infect Dis. 2021 Jul;108:209-211. doi: 10.1016/j.ijid.2021.05.050. Epub 2021 May 24.

Abstract

Multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) received initial reports regarding patients who had presented delayed and multisystem involvement of the disease, with clinical course resembling multisystem inflammatory syndrome in children (MIS-C). This study introduces a case of MIS-A, where the patient presented 3 weeks after initial COVID-19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by the CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high-dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on treatment modalities and clinical predictors.

Keywords: COVID-19; Multisystem inflammatory syndrome in adults (MIS-A); SARS-CoV-2 infection.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • COVID-19*
  • Child
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome
  • United States

Substances

  • Immunoglobulins, Intravenous
  • Interleukin 1 Receptor Antagonist Protein

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related